Characterizing Oseltamivir Use among Community-Dwelling Patients Diagnosed with Influenza Virus Infection, 2023-2025

This study of U.S. outpatient influenza cases from 2023–2025 reveals that oseltamivir initiation rates were suboptimal even among high-risk individuals, with treatment completion being particularly low among young children and overall only reaching 42% of those who started the medication.

The Gist

Imagine the flu virus as a mischievous intruder breaking into your house. Oseltamivir (the brand name is Tamiflu) is like a specialized security guard hired to chase that intruder out and stop them from causing more damage.

This study is like a detective report from two recent flu seasons (2023–2025). The researchers followed 823 people who had the flu and went to a doctor. They wanted to answer two big questions:

1. Did people actually hire the security guard? (Did they start taking the medicine?)
2. Did they let the guard stay until the job was done? (Did they finish the full course of medicine?)

Here is the story of what they found, told in simple terms.

1. The "Hiring" Problem (Initiation)

The study found that only about 4 out of 10 people actually started taking the medicine, even though doctors often recommend it for people who are at higher risk of getting very sick (like young children, older adults, or those with chronic health issues).

• The "Toddler Trap": The researchers noticed a strange pattern with young kids. While older adults (65+) were very likely to get the medicine (67%), children between the ages of 2 and 5 were the least likely to get it (only 19%).
  • Analogy: It's like a fire department that rushes to save a burning mansion (the older adult) but forgets to send a truck to the small, fragile treehouse (the 2-to-5-year-old), even though the treehouse is just as likely to burn down.
• The "Too Late" Factor: If people waited more than two days after their symptoms started to see a doctor, they were much less likely to get the medicine.
  • Analogy: Oseltamivir works best like a fire extinguisher used immediately when you see smoke. If you wait until the whole house is on fire (3+ days later), the doctor might think, "It's too late to use the extinguisher," and just hand you a bucket of water instead.

2. The "Quit Too Soon" Problem (Completion)

Of the people who did start taking the medicine, less than half finished the full prescription. The recommended "job" is 10 doses (taking a pill twice a day for 5 days).

• The "Stop When You Feel Better" Trap: Many people stopped taking the pills as soon as they started feeling better.
  • Analogy: Imagine you are painting a fence. You paint the first half, the wood looks nice, and you think, "I'm done!" But the fence is only half-painted, and the rain (the virus) is coming back to ruin your work. You need to paint the whole fence to get the full protection.
• The "Tiny Tots" Struggle: The group that finished the least amount of medicine were babies and toddlers under 2 years old. Only about 1 in 4 of them finished the full course.
  • Analogy: Giving medicine to a toddler is like trying to get a toddler to eat a full bowl of broccoli. They might take a few bites (doses) and then refuse to eat anymore, leaving the "bowl" (the treatment) unfinished.

3. Why Does This Matter?

The researchers found that timing and finishing the job are the keys to success.

• If you start the "security guard" early (within 48 hours), they are much more effective.
• If you let the guard leave early (stop taking pills), the intruder (flu virus) might come back stronger.

The Big Takeaway

This study is a wake-up call. Even though we have a great tool (Oseltamivir) to fight the flu, we aren't using it enough, and when we do use it, we often don't use it all the way through.

• For Parents: If your young child gets the flu, ask the doctor about the medicine early, and make sure they finish the whole bottle, even if they start feeling better.
• For Everyone: Don't wait until you feel terrible to see a doctor. The sooner you get help, the better the "security guard" can do their job.

In short: We have the shield, but we need to put it on faster and hold it up longer to really protect ourselves and our families.

Technical Summary

1. Problem Statement

Influenza remains a significant public health burden, causing severe illness and complications, particularly among high-risk populations (e.g., young children, elderly, and those with comorbidities). Oseltamivir is the most widely prescribed antiviral for influenza, recommended by the CDC and AAP to be initiated within 48 hours of symptom onset for high-risk groups to reduce symptom duration and complications.

Despite these guidelines, there is a lack of granular, real-world data regarding:

• Initiation Rates: The actual proportion of high-risk outpatients who initiate oseltamivir, specifically broken down by age and risk factors in recent seasons.
• Course Completion: The rate at which patients complete the full recommended course (5 days or 10 doses), as incomplete courses may diminish clinical efficacy.
• Disparities: Whether specific subgroups (e.g., young children vs. elderly) are systematically undertreated or fail to complete therapy.

2. Methodology

Study Design & Population:

• Type: Prospective, case-ascertained household transmission study (Respiratory Viral Transmission Network or RVTN).
• Period: 2023–2024 and 2024–2025 influenza seasons.
• Location: Three US academic medical centers in Tennessee, New York, and Missouri.
• Cohort: 823 "index participants" (the first household member to test positive for influenza) aged 0–96 years who sought outpatient or emergency care.
• Inclusion Criteria: Laboratory-confirmed influenza, positive test within 5 days of symptom onset, residence with at least one other person, and no household members with prior symptoms.

Data Collection:

• Surveillance: Participants completed daily diaries for up to 12 days (retrospective from symptom onset to enrollment, then prospective for 7 days).
• Variables: Self-reported medication usage (specifically oseltamivir, baloxavir, zanamivir), symptom severity, sociodemographics, vaccination history (verified via records), and pre-existing conditions.
• Definitions:
  • Initiation: Taking $\ge$ 1 dose of oseltamivir.
  • Completion: Taking $\ge$ 10 doses (representing the full 5-day course).
  • High-Risk Status: Age <5 (especially <2), age $\ge$65, or presence of comorbidities (heart disease, asthma, cancer, diabetes, kidney/liver/immune conditions, obesity).

Statistical Analysis:

• Descriptive: Calculated initiation and completion rates stratified by age, risk status, site, and care setting.
• Regression: Unadjusted and adjusted logistic regression models were used to identify factors associated with initiation and completion.
  • Covariates: Season, sex, age, study site, care setting, pre-existing conditions, and vaccination status.
  • Selection: Bidirectional Akaike Information Criterion (AIC) stepwise selection was used for model building.

3. Key Contributions

• Granular Real-World Data: Provides one of the first detailed descriptions of individual oseltamivir dosing courses in the US outpatient setting during non-pandemic seasons (2023–2025).
• Focus on Completion: Moves beyond prescription rates to analyze adherence (completion of $\ge$10 doses), a critical metric often missing in claims-based studies.
• Identification of Treatment Gaps: Highlights specific demographic disparities, particularly the low initiation rates in children aged 2–5 years and low completion rates in children <2 years.
• Contextualization: Contrasts current findings with historical data (e.g., 2009 pandemic) and recent claims-based studies to show persistent gaps in guideline adherence.

4. Key Results

Demographics:

• Total analyzed: 823 participants.
• High-risk population: 49% (406/823).
• Age distribution: 50% aged 5–17, 13% aged 2–<5, 6% aged <2.

Oseltamivir Initiation:

• Overall Rate: 39% (324/823) of all influenza-positive outpatients initiated oseltamivir.
• High-Risk Rate: Only 42% (172/406) of high-risk individuals initiated treatment.
• Age Disparities:
  • Lowest: Children aged 2 to <5 years (19%).
  • Highest: Adults aged $\ge$65 years (67%) and children <2 years (42%).
• Risk Factors:
  • Presence of pre-existing conditions increased odds of initiation (aOR: 1.98 unadjusted; significant in adjusted models).
  • Children aged 2–<5 were significantly less likely to initiate compared to adults 18–50 (aOR: 0.30).
  • Geographic variation: Tennessee had significantly higher initiation rates than New York (aOR: 2.41).
• Timing: Initiation was more common when care was sought within 48 hours of symptom onset (45%) compared to >48 hours (26%).

Oseltamivir Course Completion:

• Overall Rate: Among those who initiated (n=313 for this subset), only 42% completed the recommended $\ge$10 doses.
• Age Disparities in Completion:
  • Lowest: Children <2 years (25%).
  • Moderate: Adults $\ge$65 (31%).
  • Highest: Children aged 2–<5 years (56%).
• Risk Factors:
  • Children <2 years were significantly less likely to complete the course compared to adults 18–50 (aOR: 0.21, 95% CI: 0.04–0.78).
  • No other variables (sex, site, vaccination, comorbidities) reached statistical significance for completion in adjusted models.
• Symptom Correlation: No significant difference in reported symptoms (including GI symptoms) was found between those who completed vs. discontinued treatment, suggesting reasons for discontinuation were not captured by symptom severity.

5. Significance and Implications

• Public Health Gap: The study reveals a critical disconnect between clinical guidelines and real-world practice. Despite the 2024–2025 season being classified as high severity, less than half of high-risk outpatients received antiviral treatment, and fewer than half of those treated completed the full course.
• Pediatric Vulnerability: The findings highlight a specific vulnerability in pediatric populations. The extremely low initiation rate in children aged 2–5 and the low completion rate in children <2 suggest barriers in provider prescribing habits, parental adherence, or concerns about side effects (e.g., gastrointestinal issues) that are not fully captured by symptom reporting.
• Clinical Outcomes: Incomplete courses may reduce the therapeutic benefit of oseltamivir, potentially leading to prolonged viral shedding, increased symptom duration, and higher rates of complications or transmission.
• Future Directions: The authors suggest a need for improved provider education regarding early initiation (even beyond 48 hours for high-risk groups) and enhanced patient counseling to ensure course completion. The data underscores the necessity for interventions targeting specific age groups and geographic regions to align practice with CDC and AAP recommendations.

Limitations Noted: Self-reported data (potential recall bias), small sample sizes in specific pediatric subgroups limiting statistical power, and the study population being restricted to academic medical center attendees (potentially not representative of all US outpatient settings).